Sanara MedTech Inc. (SMTI) stock
Close on Nov 11, 2026Market cap $290.43MP/E –Yield –
Sanara MedTech Inc. grew revenue 13.0% to $109.81M over the twelve months to Jun 30, 2026. Operating income rose 32.5% to $8.42M, moving the operating margin from 6.5% to 7.7%. Free cash flow was $4.50M, up 5368.1% from a year earlier. At the latest close the market valued the company at $290.43M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $290.43M
- P/E ratio
- –
- Price to sales
- 2.64
- Price to book
- 36.56
- Dividend yield
- –
- Free cash flow yield
- 1.55%
Fundamentals
- Revenue
- $109.81M
- Net income
- -$32.01M
- EPS, diluted
- -$3.61
- Free cash flow
- $4.50M
- Book value per share
- $0.92
- Diluted shares
- 9M
Trading
- Next earnings
- Nov 11, 2026 (estimated, before the open)
- Previous close
- $31.66
- Open
- $31.82
- Day's range
- $31.61 – $31.92
- Volume
- 42,562
- Average volume (20 days)
- 105,957
- Index membership
- Russell 2000 (since Jun 2023)
- Beta (5 years)
- 0.89
- 52-week range
- $16.05 – $35.52
- RSI (14 days)
- 29.2
- Volatility (1 year)
- 57.2%
- Relative volume
- 0.18×
- WACC
- 9.7%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | SMTI | S&P 500 | Difference | SMTI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -9.9% | -2.4% | −7.5 pts | ||
| 3 months | -8.1% | -1.2% | −6.9 pts | ||
| Year to date | +35.4% | +12.3% | +23.1 pts | ||
| 1 year | +12.7% | +12.4% | +0.3 pts | ||
| 3 years | +10.1% | +78.8% | −68.7 pts | +3.3% | +21.4% |
| 5 years | -7.4% | +75.2% | −82.6 pts | -1.5% | +11.9% |
| 10 years | +690.3% | +311.1% | +379.1 pts | +23.0% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Sanara MedTech filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Update
- Results
About Sanara MedTech
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Sanara MedTech Inc. is a medical technology company that develops and commercializes surgical solutions focused on tissue repair and bone fusion. Operating through a single reportable segment, the company provides products for sterile operating room environments. Its soft tissue offerings include CellerateRX Surgical, a hydrolyzed collagen used to manage surgical wounds, and BIASURGE, a surgical wound irrigation solution. It also supplies bone fusion and orthobiologic products, such as BiFORM bioactive moldable matrix and ALLOCYTE Plus cellular bone matrix. The company primarily sells its products to surgeons, hospitals, and ambulatory surgical centers.
Company profile, executives and historySanara MedTech stock: common questions
What is Sanara MedTech's stock price?
SMTI closed at $31.61 on Nov 11, 2026, down 0.16% on the day. Over the past 52 weeks it traded between $16.05 and $35.52.
What is Sanara MedTech's market cap?
Sanara MedTech was worth $290.43M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is SMTI's P/E ratio?
Sanara MedTech lost money over the twelve months to Jun 30, 2026 (diluted EPS -$3.61), so it has no meaningful P/E ratio.
How much revenue does Sanara MedTech make?
Sanara MedTech reported revenue of $109.81M for the twelve months to Jun 30, 2026, up 13.0% from a year earlier.
Does Sanara MedTech pay a dividend?
No. Sanara MedTech has not paid a cash dividend over the last twelve months.
When does Sanara MedTech report earnings next?
Sanara MedTech is expected to report Q3 FY2026 results on Nov 11, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has SMTI stock performed over the past year?
Including dividends, SMTI returned +12.7% over the past year, against +12.4% for the S&P 500.
How many SMTI shares are sold short?
0M shares were sold short at the latest FINRA report, 5.27% of the float, or 3.2 days of average trading volume.
Who are Sanara MedTech's competitors?
Companies most similar to Sanara MedTech by business, industry and size include XTNT, TELA, ANIK, SI, AXGN.
See a number that looks wrong?